item management s discussion and analysis of financial condition and results of operations the following discussion should be read in conjunction with the consolidated financial statements and notes thereto  which are included herein 
background since  the company has raised funds of some  from equity and debt financing which has been used in research and development of its nucleic acid technologies 
nucleic acid compounds represent a new class of pharmaceutical products designed to act at the molecular and genetic level for the definitive treatment of certain devastating human diseases 
the company s platform technology utilizes specifically configured ribonucleic acids rna which are broadly protected by a patent estate consisting of more than patents 
one of the company s double stranded rna drug products  trademarked ampligen  is in advanced human clinical development for various therapeutic indications 
based on the results of pre clinical and clinical trials  the company believes that ampligen may have broad spectrum anti viral and anti cancer potential 
over patients have participated in clinical trials authorized by the food and drug administration fda at some twenty clinical sites across the united states  representing the administration of more than  doses 
in october   the company initiated a phase iii trial for the treatment of patients afflicted with myalgic encephalomyelitis chronic fatigue syndrome me cfs at various medical centers in the united states 
in parallel  the company is conducting cost recovery treatment programs for me cfs patients in the united states  canada  belgium and austria 
the treatment program in the us was expanded by fda authorization in early in december   the company completed and filed a full marketing application for approval to treat me cfs patients in the european union 
the company is actively engaged in various market development strategies in the united states and european union  as well as other countries including canada  australia and south africa 
disease categories under active development include me cfs  hepatitis and hiv 
the company maintains offices and clinical operations in both the united states and european union  as well as ownership interests in a related european based diagnostic company and in a south african manufacturing entity which produces its raw drug materials 
the company has reported net income only from through since  the company has incurred substantial operating losses 
prior to completing an initial public offering ipo in november  the company financed operations primarily through the private placement of equity and debt securities  equipment lease financing  interest income and revenues from licensing and royalty agreements 
the consolidated financial statements include the financial statements of hemispherx biopharma  inc and its four wholly owned subsidiaries  biopro corp  bioaegean corp  core biotech corp 
and hemispherx biopharma europe nv sa 
the us subsidiaries were incorporated in september for the purpose of developing technology for ultimate sale into certain nonpharmaceutical specialty consumer markets 
the european subsidiary was formed for the purpose of serving the company s needs with respect to pursuing clinical trials and regulatory approval in the european union 
all significant intercompany balances and transactions have been eliminated in consolidation 
the company expects to continue its research and clinical efforts for the next several years with some benefit of certain revenues from cost recovery treatment programs  notably in belgium  canada and the us 
beginning in  limited revenues were initiated in belgium from sales under the cost recovery provision for conducting treatment clinical tests in me cfs  including the united states these sales were  in the company may continue to incur losses over the next several years due to clinical costs which may be partially offset by expanded access cost recovery revenues and potential licensing fees 
such losses may fluctuate from quarter to quarter as a result of differences in the timing of significant expenses incurred and receipt of licensing fees and or revenues 
acquisition of full or conditional marketing approval in any major market would significantly affect the company s cash flow 
there are no assurances that such approvals will ever happen in any major pharmaceutical market 
results of operations years ended december  vs 
the company reported a net loss of  including a non cash loss of  for stock compensation expense for the year ended december  versus a net loss of  for the same period in several factors contributed to the  increase in net losses in in general  non operating stock compensation expense  increased clinical costs and legal fees account for the increase in net losses 
revenues from the company s cost recovery treatment program in the united states and europe were up by  in versus the company expects these programs may expand in the year  especially in europe where efforts are being organized to increase the expanded access program to other european countries 
at present  these programs are operational in belgium and austria 
in  clinical trial costs increased  primarily due to increased activity in the amp me cfs clinical trial initiated by the company in october  manufacturing and related costs were  in versus  in the costs reflects the build up of drug inventories needed to support clinical trial and other research and development efforts 
at present  the company expenses all raw material and related production costs as incurred 
general and administrative expenses were up  in versus legal expenses for attorneys increased  primarily due to litigation associated with the asensio company lawsuit  the ell co 
lawsuit  settlement of the vmw lawsuit and other legal matters 
expenses associated with stock transactions  registration statements and financing were up  the cost of funding the european operation was up by  in due to establishing and some staffing of the company s european subsidiary 
the cost of evaluating the feasibility of the spin off of the company s wholly owned subsidiary was  more than expensed in stock compensation expense was  for versus  recorded for stock compensation expenses reflect the fair value of the common stock including the warrants granted to non employees of the company 
the increase in reflects warrants granted to consultants for various types of assistance and professional services provided to the company 
years ended december  vs 
the company reported a loss of  in versus a loss of  in several factors contributed to the increased loss of  in revenues increased by  in due to the increased enrollment of patients in the cost recovery treatment programs being conducted in belgium  canada and the united states 
research and development costs increased  in due primarily to increased spending to start up the phase iii me cfs clinical trial in the united states 
in addition  the company built up the inventory of ampligen raw materials and finished goods in anticipation of the drug needs to support the phase iii clinical trial 
all costs incurred were part of the company s plan to enhance the clinical data required to support the eventual full marketing application in the united states and european union 
general and administration expenses totaling  in increased  over the prior year 
litigation issues that arose in caused an increase in legal fees by approximately  preparation and filing of the european union new drug application resulted in consultant and related expenses to increase a total of  public relations shareholder communications expense increased by some  as the company responded to various charges brought by short sellers see asensio litigation and administrative expenses supporting clinical trials increased  consulting stock compensation expense of  in relates to the stock value of warrants granted to consultants engaged to assist the company on various financial  stock market and other matters 
preferred stock conversion expense of  in primarily resulted from the inducement to effect the early redemption of the series d preferred stock 
the company gave the preferred stockholder  shares of common stock with a guaranteed sales price of per share 
interest income was  in versus  in while overall short term interest rates were lower than those experienced in  the amount of unused funds available for short term investing was greater causing the increase in interest income 
liquidity and capital resources cash  cash equivalents and short term investments at december  was  reflecting a net use of cash totaling  in operating activities used  non operating expenditures totaled  cash proceeds include  from private placements of the company stock and  from warrantholders exercising warrants 
cash used for non operating items include  used to acquire  of the company s common stock pursuant to a share buy back program approved by the company s board of directors 
the company privately placed  of these shares producing proceeds of  in addition  the company spent  to acquire an interest in an unconsolidated affiliate 
 was spent on equipment primarily computers and software and patents 
the company s operating cash burn rate for the last six months of was approximately  per month 
all clinical trial drug products were fully expensed although some are expected to be sold under the expanded access  recovery  pre marketing programs authorized by fda and various regulatory bodies in other countries 
as the clinical testing effort in the united states accelerates and the european market development activity increases  the operating burn rate may increase periodically 
however  certain of the operating  as well as the non operating cash outlays are of a one time nature and are expected to decline significantly 
also revenues from expanded access product sales is expected to continue to increase in the coming year 
the company expects warrant holders to continue exercising the class a redeemable warrants and private warrants from time to time depending on the trading price of the company common stock 
as of december   the company has  class a redeemable warrants outstanding 
these warrants can be exercised at per share 
in addition  there are  class a redeemable warrants outstanding at an exercise price of per share 
non public warrants outstanding total  with a weighted average exercise price of 
because of the company s long term capital requirements  it may seek to access the public equity market whenever conditions are favorable  even if it does not have an immediate need for additional capital at that time 
any additional funding may result in significant dilution and could involve the issuance of securities with rights which are senior to those of existing stockholders 
the company may also need additional funding earlier than anticipated  and the company s cash requirements in general may vary materially from those now planned  for reasons including  but not limited to  changes in the company s research and development programs  clinical trials  competitive and technological advances  the regulatory process  and higher than anticipated expenses and lower than anticipated revenues from certain of the company s clinical trials for which cost recovery from participants has been approved 
new accounting pronouncements on december   the securities and exchange commission  or sec  issues staff accounting bulletin no 
 revenue recognition in financial statements  or sab no sab no 
provides the sec staff s views on the recognition of revenue including nonrefundable technology access fees received by biotechnology companies in connection with research collaborations with third parties 
sab no 
states that in certain circumstances the sec staff believes that up front fees  even if nonrefundable  should be deferred and recognized systematically over the term of the research agreement 
sab no 
requires registrants to adopt the accounting guidance contained therein by no later than the second fiscal quarter of the fiscal year beginning after december  the adoption of this standard should not have a material impact on the company s financial position of results of operations 
in june  the fasb issued statement of financial accounting standards no 
 accounting for derivative instruments and hedging activities statement 
statement establishes accounting and reporting standards for derivative instruments  including certain derivative instruments embedded in other contracts  and for hedging activities 
statement requires that an entity recognize all derivatives as either assets or liabilities in the statement of financial position and measure the instrument at fair value 
the accounting changes in the fair value of a derivative depend on the intended use of the derivative and the resulting designation 
this statement  as amended  is effective for the first fiscal quarter beginning after december  the adoption of this standard will not have a material impact on the company s earnings or financial position 
item a 
quantitative and qualitative market risk market risk the company had million in cash and cash equivalents at december  to the extent that the company s cash and cash equivalents exceed its near term funding requirement  the company invests the excess cash on to months high quality financial instruments 
the company employs established policies and procedures to manage any risks with respect to any investment exposure 

